Featured news from NHIVNA
HIV-related news from NAM
Tenofovir resistance may develop after HIV treatment failure in over half in sub-Saharan Africa
Keith Alcorn, 2016-02-01 17:30:00
More than half of people who experienced failure of a
tenofovir-based antiretroviral regimen in sub-Saharan Africa had resistance to
tenofovir, a meta-analysis of drug resistance studies published in Lancet Infectious Diseases has shown.
The study found that the prevalence of tenofovir resistance after first-line failure ranged from 20% in Western Europe and North America to 56% - 60% in sub-Saharan Africa.
The authors say that their findings suggest that somewhere between 7.5% and 17.5% of people who start treatment in sub-Saharan Africa, with a regimen composed of tenofovir, efavirenz and either lamivudine or emtricitabine, will develop tenofovir resistance after one year, based on current rates of treatment failure. This projection assumes a treatment failure rate of between 15% and 35%, depending on how it is measured, and is in line with recent WHO estimates.